CClinicalTrials.gg
Status unknownNCT03301974Updated Jan 9, 2019

A Comparison Between Surgical Techniques for Securing Conjunctival Autografting in Primary Pterygium Surgery

An interventional study of conjunctival autograft with fibrin glue and sutured conjunctival autograft in Pterygium, sponsored by Assiut University. Status unknown. Per ClinicalTrials.gov, last updated 2019-01-09.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2019), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Study summary

Pterygium is a fibrovascular wing shaped encroachment of conjunctival fold on to the cornea with elastotic degeneration of a subconjunctival tissue, The standard treatment for pterygium is surgical excision, but the recurrence rate after surgery can be as high as 24%-89%, which compromises outcomes. Based on the simple excision of pterygium, multiple strategies and techniques have been developed to reduce the high rate of pterygium recurrence. The investigators aim was to compare the safety, efficacy, overall patient satisfaction and recurrence rate of suturing, fibrin gluing and sutureless glue-free technique for attaching conjunctival autograft in primary pterygium surgery.

Read the detailed description

Design: Prospective randomized comparative interventional clinical study Setting: Assiut university hospital \& El-Mabarah hospital for health insurance Methods: The study included 60 eyes of 60 consecutive patients of primary nasal pterygium were enrolled in the study. Simple excision under local anesthesia was performed then closure of the bare sclera by conjunctival autograft with fibrin glue in 20 eyes of 20 patients (group 1), versus sutured free conjunctival autograft in 20 eyes of 20 patients (group 2) ), versus sutureless and glue-free conjunctival autograft in 20 eyes of 20 patients (group 3).

02

Conditions studied

  • Pterygium

Browse trials for

03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patients complaining of primary Progressive nasal pterygium.
  2. Patients with pterygium threatening the visual axis.

Exclusion criteria

Exclusion Criteria:

  1. Double head pterygium.
  2. Pseudopterygium
  3. Recurrent pterygium
  4. Patients with history of any bleeding abnormalities
  5. Patients with ocular surface diseases eg- blepharitis, Sjogren syndrome and dry eye.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    conjunctival autograft with fibrin glue

    Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision

    Procedure: conjunctival autograft with fibrin glue

  • Experimental
    sutured conjunctival autograft

    Sutured conjunctival autograft done for patients of group 2 after pterygium excision

    Procedure: sutured conjunctival autograft

  • Experimental
    sutureless and glue-free conjunctival autograft

    Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision

    Procedure: sutureless and glue-free conjunctival autograft

Interventions

  • Procedureconjunctival autograft with fibrin glue

    Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).

  • Proceduresutured conjunctival autograft

    Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).

  • Proceduresutureless and glue-free conjunctival autograft

    Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)

05

What researchers measure

Primary outcomes

  1. Recurrence Rate

    The main postoperative primary outcomes measure the recurrence rate

    Time frame: 6 months postoperatively

Secondary outcomes

  1. Graft stability

    postoperative Graft stability rated from grade 0 to 4 using a 5 point scale

    Time frame: 1 day, 2 day, 1 week, 1 month 3 months and 6 months postoperatively

  2. Postoperative inflammation

    postoperative inflammation rated from grade 0 to 4 using a 5 point scale

    Time frame: 1 day, 2 day, 1 week, 1 month 3 months and 6 months postoperatively

  3. Postoperative discomfort

    postoperative discomfort rated from 0 to 10 on the Visual Analogue Scale (VAS)

    Time frame: 1 day, 2 day, 1 week, 1 month 3 months and 6 months postoperatively

  4. Overall patient satisfaction

    Overall satisfaction with the procedure 4 weeks post-operatively will recorded as four grades 0= unsatisfied, 1= low satisfaction, 2= moderate satisfaction and 3= highly satisfied, the data were collected as mean scores and recorded. The three groups will compared for overall satisfaction.

    Time frame: 1 day, 2 day, 1 week, 1 month 3 months and 6 months postoperatively

  5. Complications

    Complications recorded including, persistent epithelial defect, dellen, inclusion cyst, pyogenic granuloma, conjunctival edema, corneal scleral necrosis, infective scleritis, keratitis and endophthalmitis.

    Time frame: 1 day, 2 day, 1 week, 1 month 3 months and 6 months postoperatively

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03301974
Lead sponsor
Assiut University
Responsible party
Mohamed Fathy Ahmed Oraby (Specialist of ophthalmology, El-Mabarah hospital for Health insurance, Assuit, Egypt, Assiut University) — Principal investigator
First posted
Oct 4, 2017
Start date
Feb 24, 2019 (estimated)
Primary completion
Dec 2019 (estimated)
Completion
Jan 2020 (estimated)
Last update
Jan 9, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion